Overview

A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy Subjects

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the effect of rifampin on the Pharmacokinetic (PK) profile of tivozanib.
Phase:
Phase 1
Details
Lead Sponsor:
AVEO Pharmaceuticals, Inc.
Treatments:
Endothelial Growth Factors
Rifampin